Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2022-07-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the completion of industrial and commercial registration changes, including changes to the company's registered address, business scope, and amendments to the company charter. It references resolutions passed at the 2021 Annual General Meeting and the filing of related documents with regulatory authorities. The document is short (1011 characters) and primarily serves as a formal notice of completed administrative changes rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for regulatory announcements and compliance documents that do not fit other specific categories.
2022-07-11 Chinese
关于董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Ms. Ye Yujun, from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the resignation, confirms no breach of commitments, and states the impact on the board. There is no financial data, no mention of reports or meetings, and the content focuses solely on management changes. This fits the category of Board/Management Information (MANG). The document length is short and it is a formal announcement of a management change, not a report or other filing type.
2022-07-01 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the board meetings approving the repurchase plans, the amounts and price limits, and the actual shares repurchased up to June 30, 2022. It also references compliance with relevant laws and stock exchange regulations. The document is relatively short (2169 characters) and focuses on the progress and regulatory compliance of the share buyback, not on financial results or other report types. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back its own shares.
2022-07-01 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a securities company (华英证券有限责任公司) regarding the use of temporarily idle raised funds by Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses the approval, usage, and management of the raised funds from a non-public issuance of A shares in 2020, including investment projects, cash management products, risk control, and approvals by the board and independent directors. The document is not a full annual or interim financial report, nor is it an earnings release or a regulatory filing of a different nature. It is a specialized audit or verification opinion related to the use of raised funds and cash management, which fits the definition of an Audit Report / Information (AR) as it involves an audit opinion and compliance verification by the sponsor institution. The document length is under 5,000 characters but contains substantive content and detailed analysis, not merely an announcement or certification letter, so it is not an RPA or RNS. Therefore, the best classification is AR with high confidence. Q1 2022
2022-06-28 Chinese
独立董事关于公司有关事项所发表的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement of independent directors expressing their independent opinion regarding the company's use of temporarily idle raised funds for cash management. It references relevant laws and company rules, and confirms that the procedures and approvals were legal and compliant. The document is short (595 characters) and does not contain financial statements or detailed financial data. It is not an annual report, audit report, or financial report, but rather an official opinion or regulatory compliance statement. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-06-28 Chinese
关于使用部分闲置募集资金现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the approval by the board and supervisory committee, the amount and purpose of the cash management, risk analysis, and opinions from independent directors and sponsors. The document is a formal disclosure about the company's financing fund usage and cash management activities, not a financial report or earnings release. It is a regulatory announcement about capital usage and management of raised funds, fitting the category of Capital/Financing Update (CAP). The document length is 4424 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the best classification is CAP with high confidence.
2022-06-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.